12th EDRN Scientific Workshop - Wednesday 24 March Agenda
20th Year of EDRN: Making Cancer Detection Possible
Wednesday, March 24, 2021 (10:00 a.m. - 5:45 p.m. Eastern Daylight Time)
|
10:00 a.m. - 10:05 a.m. EDT (all times Eastern Daylight Time) |
Welcome Joshua LaBaer, MD, PhD, Arizona State University/The Biodesign Institute Arul Chinnaiyan, MD, PhD, University of Michigan Sudhir Srivastava, PhD, MPH, National Cancer Institute |
| 10:05 a.m. - 10:25 a.m. EDT |
17: Cancer Biomarkers and Disparity in Underserved Populations Olufunmilayo Olopade, MD, FACP, University of Chicago Medicine |
| 10:25 a.m. - 10:30 a.m. EDT | Q&A |
| 10:30 a.m. - 1:15 p.m. EDT | Session 4 - Academic-Industry Partnership Forum |
| 10:30 a.m. - 10:35 p.m. EDT |
Introduction to the Session Moderator: Ernest Hawk, MD, MPH, The University of Texas MD Anderson Cancer Center |
| 10:35 a.m. - 10:50 a.m. EDT |
18: A Revolution in Early Cancer Detection Josh Ofman, MD, MSHS, GRAIL, Inc. |
| 10:50 a.m. - 11:05 a.m. EDT |
19: Systems-level thinking facilitating the introduction of Multi-Cancer Early Detection (MCED) tests Peter Keeling, Diaceutics |
| 11:05 a.m. - 11:20 a.m. EDT |
20: Multi-Cancer Early Detection: The Challenges to Be Overcome to Reach the Goal of MCDE Kathryn Lang, MD, Guardant Health |
| 11:20 a.m. - 11:35 a.m. EDT | Break |
| 11:35 a.m. - 11:50 a.m. EDT |
21: Multi-cancer screening guides patient management in a study enabled by academia-health system- industry partnership Isaac Kinde, MD, PhD, Thrive Detect |
| 11:50 a.m. - 12:05 p.m. EDT |
22: TBD Graham Lidgard, PhD, Exact Sciences |
| 12:05 p.m. - 1:15 p.m. EDT |
Panel Discussion Eric Fung, MD, PhD, GRAIL, Inc. Daniel Chan PhD, Johns Hopkins University Johan Skog, PhD, Exosome Diagnostics Reena Philip, PhD, Food and Drug Administration Nickolas Papadopoulos, PhD, Johns Hopkins University |
| 1:15 p.m. - 1:30 p.m. EDT | Break |
| 1:30 p.m. - 3:30 p.m. EDT | Session 5 - Public Health Consideration of Biomarker Research |
|
Speakers will summarize the highlights of the topics that were discussed by the EDRN Steering Committee in October 2020 Moderators: Philip Castle, PhD, MPH, National Cancer Institute tentative Ruth Etzioni, PhD, Fred Hutchinson Cancer Research Center |
|
| 1:30 p.m. - 1:50 p.m. EDT |
23: What Target Sensitivity and Specificity Might Confer Clinical Utility? Steve Skates, PhD, Massachusetts General Hospital/Harvard Robert Schoen, MD, University of Pittsburgh Cancer Institute |
| 1:50 p.m. - 2:00 p.m. EDT | Q&A |
| 2:00 p.m. - 2:20 p.m. EDT |
24: MAPBD – Model-based Augmentation of the Phases of Biomarker Development for a New Era of Early Detection Ruth Etzioni, PhD, Fred Hutchinson Cancer Research Center |
| 2:20 p.m. - 2:30 p.m. EDT | Q&A |
| 2:30 p.m. - 3:05 p.m. EDT |
25: Health Disparity and Biomarker Research Christopher Li, MD, PhD, Fred Hutchinson Cancer Research Center Timothy P. Quinn, MD, Emory University School of Medicine Pierre Massion, MD, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center Guest Speaker: Melissa Davis, PhD, Weill Cornell College of Medicine |
| 3:05 p.m. - 3:15 p.m. EDT | Q&A |
| 3:15 p.m. - 3:35 p.m. EDT |
26: Study Designs for Clinical Utility Trials Yingye Zheng, PhD, Fred Hutchinson Cancer Research Center Steve Skates, PhD, Massachusetts General Hospital/Harvard |
| 3:35 p.m. - 3:45 p.m. EDT | Q&A |
| 3:45 p.m. - 4:00 p.m. EDT | Break |
| 4:00 p.m. - 5:45 p.m. EDT |
Session 6 - EDRN Early Stage Investigators Presentations Moderators: Karin Rodland, PhD, Pacific Northwest National Laboratory Andrew Kossenkov, PhD, The Wistar Institute |
| 4:00 p.m. - 4:12 p.m. EDT |
27: Combinatorial Biomarker(s) for Pancreatic Cancer Diagnosis: Lessons from Transcriptome Sukhwinder Kaur, PhD, University of Nebraska Medical Center |
| 4:12 p.m. - 4:15 p.m. EDT | Q&A |
| 4:15 p.m. - 4:27 p.m. EDT |
28: Building a Radiogenomic Portrait of Pancreatic Intraductal Papillary Mucinous Neoplasm Jennifer Permuth, PhD, MS, H. Lee Moffitt Cancer Center and Research Institute |
| 4:27 p.m. - 4:30 p.m. EDT | Q&A |
| 4:30 p.m. - 4:42p.m. EDT |
29: Digital Microfluidic Methylation Assays for the Detection of Early-Stage Ovarian Cancer Thomas Pisanic, PhD, Johns Hopkins University |
| 4:42 p.m. - 4:45 p.m. EDT | Q&A |
| 4:45 p.m. - 4:57 p.m. EDT |
30: Urine Based Early Detection of High-Grade Prostate Cancer In A Racially Diverse Patient Population Indu Kohaar, PhD, Center for Prostate Disease Research |
| 4:57 p.m. - 5:00 p.m. EDT | Q&A |
| 5:00 p.m. - 5:12 p.m. EDT |
31: MyProstateScore (MPS) Jeff Tosoian, MD, MPH, University of Michigan |
| 5:12 p.m. - 5:15 p.m. EDT | Q&A |
| 5:15 p.m. - 5:27 p.m. EDT |
32: Methylomic Biomarkers in GI Cancers: A Multi-phasic Case Study in Hepatocellular Cancer John Kisiel, MD, Mayo Clinic |
| 5:27 p.m. - 5:30 p.m. EDT | Q&A |
| 5:30 p.m. - 5:42 p.m. EDT |
33: Advancing MS-Based Single-Cell Proteomics Tao Liu, PhD, Pacific Northwest National Laboratory |
| 5:42 p.m. - 5:45 p.m. EDT | Q&A |
| 5:45 p.m. EDT | Adjourn for the Day |